REPL - NASDAQ
Replimune Group, Inc.
$10.54
+19%Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
At a Glance
Live Snapshotrepl
Total Debt
Last Annual Value
76.17M
3-Year CAGR
32%
5-Year CAGR
13%
10-Year CAGR
%
Replimune Group, Inc. Competitors Analysis of Total Debt
| Company | Total Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Replimune Group, Inc. NASDAQ:REPL | 76.17M | 7.8% | 18.0% | N/A | |
 Ginkgo Bioworks Holdings, Inc. NYSE:DNA | 417.08M | 20.3% | 78.5% | N/A | |
 MBX Biosciences, Inc. Common Stock NASDAQ:MBX | 596.00K | 22.5% | N/A | N/A | |
 MeiraGTx Holdings plc NASDAQ:MGTX | 88.69M | -0.2% | 30.2% | 144.8% | |
 Prime Medicine, Inc. NASDAQ:PRME | 116.43M | 104.4% | 62.1% | N/A | |
 Astria Therapeutics, Inc. NASDAQ:ATXS | 5.35M | 153.4% | 71.1% | -0.7% | |
 Arvinas, Inc. NASDAQ:ARVN | 8.50M | 38.5% | 11.2% | 34.0% | |
 ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | 14.00K | -64.7% | N/A | N/A | |
 Iovance Biotherapeutics, Inc. NASDAQ:IOVA | 48.44M | -13.9% | -7.5% | N/A | |
 Vir Biotechnology, Inc. NASDAQ:VIR | 186.91M | 14.5% | 6.3% | N/A |
Replimune Group, Inc. Fair Value Envelope
Related Guides
Continue your REPL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.